checkAd
    Startseite > Aktien > Cassava Sciences > Nachrichten
    Cassava Sciences Aktie
    21,730
     
    USD
    +4,77 %
    +0,990 USD
    Letzter Kurs 02:00:00 Nasdaq
    21,720
     
    USD
    800 STK
    Geldkurs 25.04.24
    21,730
     
    USD
    900 STK
    Briefkurs 25.04.24
    ISIN: US14817C1071 · WKN: A2PGL8 · SYM: SAVA · USA

    Neueste Nachrichten

    Redemption Date Announced for Warrants
    15.04.24 · globenewswire · Cassava Sciences
    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
    25.03.24 · globenewswire · Cassava Sciences
    Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference
    04.03.24 · globenewswire · Cassava Sciences
    Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
    28.02.24 · globenewswire · Cassava Sciences
    SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    11.02.24 · Business Wire (engl.) · Cassava Sciences
    No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
    07.02.24 · globenewswire · Cassava Sciences
    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
    05.02.24 · Business Wire (engl.) · Cassava Sciences
    SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    05.02.24 · Business Wire (engl.) · Cassava Sciences
    Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
    05.01.24 · globenewswire · Cassava Sciences
    Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
    07.11.23 · globenewswire · Cassava Sciences
    Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
    06.11.23 · globenewswire · Cassava Sciences
    MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
    25.10.23 · globenewswire · Cassava Sciences